Viewing nowCombinationRinacomby Sustained-release Tablet 2.5/1000 mg (Linagliptin, Metformin)
Metformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Aprogen Pharmaceuticals, Co., Ltd.

MFDS item code 202400573 · Approved 2024.03.19 · Insurance code 645210900
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps improve blood sugar control in patients with type 2 diabetes by acting with Linagliptin and Metformin together. It is primarily used to complement diet and exercise therapy, effectively lowering blood sugar levels to support diabetes management. Therefore, this medication plays a crucial role in the treatment of type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one 5/1000 mg extended-release tablet once daily. Patients taking the 2.5/1000 mg extended-release tablet should take two tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, discontinue this medicine immediately.
This medication contains Metformin and Linagliptin, which assist in blood sugar control. Care should be taken as this medication may rarely cause a serious metabolic complication known as lactic acidosis. Patients with severely impaired kidney function, those with acute disease states, patients with liver dysfunction, and those with acute alcohol intoxication should not take this medication. Additionally, those allergic to any components of this drug, patients with type 1 diabetes or diabetic ketoacidosis should not use it. This medication may cause hypoglycemia, hence it is important to closely monitor blood sugar changes when used in combination with sulfonylureas or insulin, and dose adjustments may be necessary. While taking this medication, do not skip meals to avoid low blood sugar, and avoid excessive exercise or alcohol consumption. Kidney function should be regularly monitored, and if kidney function declines, the use of this medication should be discontinued or adjusted. Prior to surgery or tests requiring radiation iodinated contrast agents, this medication should be temporarily discontinued, and usage should be resumed only after kidney function has returned to normal post-surgery. It is advisable to avoid using this medication during pregnancy, and it is recommended not to take it while breastfeeding. As it may reduce vitamin B12 levels, it is suggested to undergo regular vitamin B12 testing with prolonged use. This medication should be swallowed whole without breaking, chewing, or crushing the tablets, and it is normal for the tablet coating to be excreted in feces. Immediate medical consultation is required if sudden severe abdominal pain, persistent vomiting, muscle weakness, or difficulty breathing occurs during use. This medication may interact with other drugs, so patients must inform their doctor or pharmacist of any other medications they are taking. Elderly patients should take extra care as impaired kidney function is common, and regular kidney function tests are necessary. The impact of this medication on driving or operating machinery is unclear, yet awareness of hypoglycemia symptoms is advised. In the event of an overdose, the risk of lactic acidosis increases, necessitating an immediate hospital visit for treatment, and dialysis may be required. This medication should be stored out of reach of children, and kept away from moisture in its original container.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a sealed container. It is important to maintain storage at room temperature between 1 and 30 degrees Celsius. This will help preserve the medication's effectiveness for a longer time.
White oval sustained-release film-coated tablets engraved with AI 2.5/1000 on one side
28 tablets (7 tablets/PTPX4)/box, 30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Aprogen Pharmaceuticals, Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.